G. Tartarelli

532 total citations
18 papers, 444 citations indexed

About

G. Tartarelli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, G. Tartarelli has authored 18 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in G. Tartarelli's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Treatment and Pharmacology (4 papers) and Prostate Cancer Treatment and Research (4 papers). G. Tartarelli is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Treatment and Pharmacology (4 papers) and Prostate Cancer Treatment and Research (4 papers). G. Tartarelli collaborates with scholars based in Italy, Brazil and Japan. G. Tartarelli's co-authors include D. Amoroso, Sara Donati, Giulio A. Cinotti, Alessandro Pierucci, S Bombardieri, Andrea Camerini, Ombretta Di Munno, Carlo Patrono, Giuseppe Remuzzi and Giovanni Ciabattoni and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

G. Tartarelli

18 papers receiving 437 citations

Peers

G. Tartarelli

ONCOL

PRM

PHARM

Mi Sun Choe South Korea

An Huang China

Hikota Hayashi Japan

Nicholas Armitage United Kingdom

Jera Jeruc Slovenia

Katsunori Tauchi Japan

Paloma Guillem‐Llobat Italy

Stephen F. Sarabia United States

Farhat V. N. Din United Kingdom

Goro Kajiyama Japan

Mi Sun Choe South Korea

G. Tartarelli

129 ×0.9

ONCOL

210 ×1.5

PRM

189 ×1.6

71 ×0.9

121 ×1.6

PHARM

Citations per year, relative to G. Tartarelli G. Tartarelli (= 1×) peers Mi Sun Choe

Countries citing papers authored by G. Tartarelli

Since Specialization

Citations

This map shows the geographic impact of G. Tartarelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Tartarelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Tartarelli more than expected).

Fields of papers citing papers by G. Tartarelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Tartarelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Tartarelli. The network helps show where G. Tartarelli may publish in the future.

Co-authorship network of co-authors of G. Tartarelli

This figure shows the co-authorship network connecting the top 25 collaborators of G. Tartarelli. A scholar is included among the top collaborators of G. Tartarelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Tartarelli. G. Tartarelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Camerini, Andrea, Antonio Chella, Francesca Mazzoni, et al.. (2016). First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey. Journal of Chemotherapy. 29(1). 38–41. 1 indexed citations

Camerini, Andrea, C. Puccetti, Sara Donati, et al.. (2015). Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 15(1). 359–359. 61 indexed citations

Camerini, Andrea, C. Puccetti, Sara Donati, et al.. (2014). Phase Ii Trial of Metronomic Oral Vinorelbine As First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer (Move Trial). Annals of Oncology. 25. iv442–iv442. 1 indexed citations

Rossini, Maurizio, Maurizio Muratore, Nazzarena Malavolta, et al.. (2013). Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy. Reumatismo. 65(3). 113–20. 5 indexed citations

Camerini, Andrea, Sara Donati, Paolo Viacava, et al.. (2011). Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. Journal of Experimental & Clinical Cancer Research. 30(1). 38–38. 13 indexed citations

Camerini, Andrea, Ornella Garrone, C. Valsuani, et al.. (2009). Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients. Cancer Biology & Therapy. 8(15). 1450–1455. 2 indexed citations

Camerini, Andrea, C. Valsuani, Francesca Mazzoni, et al.. (2009). Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status. Annals of Oncology. 21(6). 1290–1295. 18 indexed citations

Valsuani, C., Andrea Camerini, Maria Laura Canale, et al.. (2009). Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases Journal. 2(1). 9133–9133. 2 indexed citations

Amoroso, D., Sara Donati, C. Valsuani, et al.. (2009). Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial). Journal of Clinical Oncology. 27(15_suppl). 1132–1132. 2 indexed citations

10.

Tibaldi, Carmelo, Enrico Vasile, Andrea Antonuzzo, et al.. (2008). First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. British Journal of Cancer. 98(3). 558–563. 8 indexed citations

11.

Sgambato, Alessandro, Andrea Camerini, D. Amoroso, et al.. (2007). Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biology & Therapy. 6(12). 1840–1846. 29 indexed citations

12.

Camerini, Andrea, et al.. (2007). Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine‐2 treatment. International Journal of Urology. 14(3). 259–260. 18 indexed citations

13.

Nicolini, Andrea, G. Tartarelli, Angelo Carpi, et al.. (2006). Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 6(1). 269–269. 51 indexed citations

14.

Nicolini, Andrea, Paola Ferrari, L Anselmi, et al.. (2004). Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomedicine & Pharmacotherapy. 58(8). 447–450. 58 indexed citations

15.

Nicolini, Andrea, Paolo Ferrari, L Anselmi, et al.. (2004). Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomedicine & Pharmacotherapy. 58(8). 447–450. 8 indexed citations

16.

Nicolini, Andrea, Angelo Carpi, Paola Ferrari, et al.. (2002). Long-term monitoring of cell-mediated immunity in disease-free breast cancer patients: a preliminary retrospective study. Biomedicine & Pharmacotherapy. 56(7). 339–344. 1 indexed citations

17.

Bombardieri, Stefano, et al.. (1987). The Clinical Relevance of Antinuclear Antibodies in Connective Tissue Diseases. Scandinavian Journal of Rheumatology. 16(sup66). 35–45. 4 indexed citations

18.

Patrono, Carlo, Giovanni Ciabattoni, Giuseppe Remuzzi, et al.. (1985). Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.. Journal of Clinical Investigation. 76(3). 1011–1018. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact